ahlam1399
08-20-2015, 04:26 PM
Lilly, Boehringer diabetes drug reduces cardiovascular risk in trial
FRANKFURT (Reuters) - A clinical trial showed that diabetes drug Jardiance, co-promoted by Eli Lilly and Boehringer Ingelheim, reduces cardiovascular risk in patients with type 2 diabetes, Boehringer Ingelheim said in a statement on Thursday.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4924bdfc/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mu-fRJs7Lo8:HJk92Y75cv8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mu-fRJs7Lo8:HJk92Y75cv8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/mu-fRJs7Lo8
FRANKFURT (Reuters) - A clinical trial showed that diabetes drug Jardiance, co-promoted by Eli Lilly and Boehringer Ingelheim, reduces cardiovascular risk in patients with type 2 diabetes, Boehringer Ingelheim said in a statement on Thursday.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4924bdfc/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mu-fRJs7Lo8:HJk92Y75cv8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mu-fRJs7Lo8:HJk92Y75cv8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=mu-fRJs7Lo8:HJk92Y75cv8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/mu-fRJs7Lo8